United StatesHealth

Henry Schein (NASDAQ:HSIC) reported second-quarter net sales of $3.458 billion, up 6.7%, with internal sales growth of 4.6%.

IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter revenue of $1.217 billion, up 10%, while diluted EPS increased 18% to $4.27.

Merck (NYSE:MRK) reported second-quarter sales of $16.61 billion, up 5%, as Keytruda and Keytruda QLEX sales reached $8.37 billion.

Revvity (NYSE:RVTY) reported second-quarter revenue of $730 million, while adjusted earnings per share increased 19% to $1.41.

SRX Global acquired an undisclosed Vistagen Therapeutics (NASDAQ:VTGN) stake on August 4, adding a late clinical-stage neuroscience investment.

Dr. Reddy’s (NYSE:RDY) announced the United States launch of Sugammadex Injection, a generic equivalent of Bridion, to expand its hospital portfolio.

Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 revenue of $219.1 million, up 32%, and announced an all-stock merger with Indivior Pharmaceuticals (NASDAQ:INDV).

CVS Health (NYSE:CVS) announced that its board of directors approved a quarterly cash dividend of $0.665 per share on its common stock, with payment scheduled for August 3, 2026.

ClearOne (NASDAQ:CLRO) said it has entered into a definitive merger agreement involving MergerSub, Vivani Medical (NASDAQ:VANI), and Cortigent, under which Cortigent will become a wholly owned subsidiary of ClearOne.

MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.

Incyte (NASDAQ:INCY) received Japanese regulatory approval for its cancer drug Minjuvi after clinical trials demonstrated response rates up to 71.4%.

Aurora Cannabis (NASDAQ:ACB) reported record global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, capitalizing on its structural pivot toward high-margin prescription markets in Europe and Australia.